A royalty-backed Technosphere platform story entering a catalyst-dense 2026, where pediatric Afrezza and Furoscix ReadyFlow could unlock a major re-rating—if execution and treprostinil competition hold.
Overview
MannKind has evolved from a niche diabetes company into a diversified commercial biopharma anchored by its Technosphere dry-powder pulmonary delivery platform. Technosphere enables ultra-rapid systemic absorption (IV-like kinetics without needles), supporting differentiated products across orphan lung, endocrinology, and cardiometabolic care. Revenue is now multi-source: product sales, royalties (notably Tyvaso DPI via United Therapeutics), manufacturing/collaboration services, and milestones. The economic center has shifted toward orphan lung through Tyvaso DPI, while Afrezza remains a core asset and Furoscix (added via scPharmaceuticals acquisition) expands into outpatient heart failure fluid management. The 2026 outlook is catalyst-driven, with two major FDA decisions (Afrezza pediatrics; Furoscix ReadyFlow) that could materially change growth, margins, and valuation.